Ketogenic diet compatible fenfluramine formulation
US11458111B2 · kind B2 · utility
5Cited by
57References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 4, 2020 |
| Grant date | Oct 4, 2022 |
| Priority date | — |
| Expiry date | Jun 25, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA23V2200/3322
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient. Also provided are compositions and kits finding use in practicing embodiments of the methods.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.